Interview
From “The Way Forward" Conference: Esther Krofah, Executive Director, FasterCures
- Treatment candidates are anticipated to advance within the next few months, potentially aligning with vaccine availability around the same time or before.
- Phase two and phase three data readouts are expected to commence by the end of summer into early fall, following study enrollment closures expected early this summer.
- Regulatory outcomes may include FDA emergency use authorizations as data reports begin or extend into evaluation through 2020 and early 2021.
- The market outlook predicts a shift toward combination solutions rather than single therapies in the eventual landscape.
- Among 163 tracked vaccine candidates, 10 are currently in clinical testing, with increased enrollment expected for Moderna and Oxford/AstraZeneca phase two studies.
- Moderna is projected to potentially enter phase three studies by July, with more individuals enrolled in phase two trials for both Moderna and Oxford/AstraZeneca vaccines.
- Potential availability is forecast for Moderna and Oxford vaccines later this year at a smaller scale targeting frontline workers and at-risk populations, with broader scale availability projected for early next year.
- Production and development timelines for certain approaches may align with a 12 to 18 month window, driven by companies risking resources to scale manufacturing.
- Risk factors include public misunderstanding regarding availability timelines, where communications about 12-month access may erroneously imply immediate universal access.